Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Magnetic Resonance in Medicine|May 21, 2025
Development and optimization of human deuterium MR spectroscopic imaging at 3 T in the abdomenMary A McLean, Ines Horvat Menih, Pascal Wodtke, et al.
Cancers|February 26, 2025
K-Means Clustering of Hyperpolarised <sup>13</sup>C-MRI Identifies Intratumoral Perfusion/Metabolism Mismatch in Renal Cell Carcinoma as the Best Predictor of the Highest GradeInes Horvat-Menih, Alixander S Khan, Mary A McLean, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 23, 2025
Spatial metabolomics informs the use of clinical imaging for improved detection of cribriform prostate cancerNikita Sushentsev, Gregory Hamm, Roido Manavaki, et al.
JCO Precision Oncology|April 6, 2019
Translating <i>in vivo</i> metabolomic analysis of succinate dehydrogenase deficient tumours into clinical utilityRuth T Casey, Mary A McLean, Basetti Madhu, et al.
Arxiv|September 21, 2023
Current Methods for Hyperpolarized [1-<sup>13</sup>C]pyruvate MRI Human StudiesPeder Ez Larson, Jenna Ml Bernard, James A Bankson, et al.
Npj Imaging|July 3, 2025
Temperature dependent chemical shifts of pyruvate and lactate enable in vivo hyperpolarized <sup>13</sup>C MRSI thermometryWolfgang Gottwald, Luca Nagel, Jason G Skinner, et al.
NMR in Biomedicine|June 24, 2026
Estimating the Sodium Content: A Case Series of Benign and Malignant Renal Tumours Using <sup>23</sup>Na-MRI at 3 TInes Horvat-Menih, Jonathan R Birchall, Maria J Zamora-Morales, et al.
Journal for Immunotherapy of Cancer|September 25, 2021
Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanomaDoreen Lau, Mary A McLean, Andrew N Priest, et al.
Magnetic Resonance in Medicine|March 5, 2024
Current methods for hyperpolarized [1-<sup>13</sup>C]pyruvate MRI human studiesPeder E Z Larson, Jenna M L Bernard, James A Bankson, et al.
Scientific Reports|July 26, 2019
Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancerSurrin S Deen, Andrew N Priest, Mary A McLean, et al.
Pageof 9